Novartis stock drops after mid-term outlook (NVS:NYSE)

JHVEPhoto/iStock Editorial via Getty Images
Novartis (NVS) shares fell in Zurich on Thursday after the Swiss drugmaker updated its mid-term guidance, indicating a 5% compound annual growth rate for net sales from 2026 to 2031 on a forex-adjusted basis.
The revised outlook fell short of
